Oxea, a global supplier of Oxo Intermediates and Oxo Derivatives, today announced for the fourth quarter of 2012 a strong earnings increase compared with the fourth quarter of 2011.
Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.
Newsletter & e-edition
News, trends and background information as well as the latest issue of CHEManager International